Exploring Combined Therapy: Disulfiram and Antifibrotic Agents in Attenuating Pulmonary Fibrosis in Bleomycin-Induced Mouse Model - Vienna 2024

Novel insights in the pathogenesis of pulmonary fibrosis

Chair(s): Manuela Funke-Chambour, Ioannis Tomos

Session type: Poster session

Exploring Combined Therapy: Disulfiram and Antifibrotic Agents in Attenuating Pulmonary Fibrosis in Bleomycin-Induced Mouse Model

MIDORI SATO

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Exploring Combined Therapy: Disulfiram and Antifibrotic Agents in Attenuating Pulmonary Fibrosis in Bleomycin-Induced Mouse Model

Midori Sato

Poster

Abstract

Altered expression of CSF1R in airway macrophages during idiopathic pulmonary fibrosis

Christina Michalaki

Abstract

Expression of HOXB7 in the lung of patients with idiopathic pulmonary fibrosis: a proof-of-concept study and clinical significance

Giulia Bruzzi

Poster

Abstract

Globularia alypum L. phenolic rich extract ameliorates progressive pulmonary fibrosis induced by Bleomycin in Wistar rats

Sana Bahri

Abstract

Genetic Deletion of Muc5b Reduces Interstitial Lung Disease in Neonatal Nedd4-2 Deficient Mice

Nathalie Smyczek

Poster

Abstract

In vitro evaluation of senolytics targeting BCL2 family members to selectively deplete senescent primary human alveolar and small airway-derived epithelial cells

Stephan Klee

Abstract

Understanding the Dynamics of Pro-Fibrotic Biomarkers in Precision-Cut Lung Slices: Implications for Preclinical Studies

Lena Willmer

Poster

Abstract

Blood levels of soluble macrophage-mannose receptor (sCD206) are uniquely associated with severity and mortality in idiopathic pulmonary fibrosis

Elisabeth Bendstrup

Poster

Abstract

Effects of the angiotensin II type 2 receptor agonist buloxibutid on human lung myofibroblasts and IPF lung tissue

Johan Raud

Poster

Abstract

Type 1 invariant natural killer T cells drive lung fibrosis

Emily Calamita

Abstract

Prognostic Significance of Pyroptosis-Related Genes in Pulmonary Fibrosis: A Risk Scoring Model Approach

Tao Yang

Poster

Abstract

LTBP2: A Potential Fibroblasts-Anchoring Target in Idiopathic Pulmonary Fibrosis Regulated by TCF4

Lingxiao Qiu

Abstract

Antifibrotics and PDE4B inhibition supress pulmonary fibroblast proliferation

Lavanya Raman

Poster

Abstract

Reproducible lung protective effects of a TGF?R1/ALK5 inhibitor in the bleomycin-induced and spirometry-confirmed mouse model of IPF

Susanne Pors

Poster

Abstract

Feasibility study of a novel synchrotron-based imaging method to assess bleomycin-induced pulmonary fibrosis progression in mice in vivo

Robert Skomro

Poster

Abstract

Sirtuins as biomarkers of accellerated cellular senescence in patients with Idiopathic Pulmonary Fibrosis (SIR-IPF)

Domenica Francesca Mariniello

Poster

Abstract

Role and mechanism of microRNA-423-5p targrted FOXP4 regulation in pulmonary fibrosis

Yi Chen

Poster

Abstract

Clinical Application of Exosome KL-6 Detection in Respiratory Diseases

Huimin Huang

Abstract

SMTP-44D, a soluble epoxide hydrolase inhibitor, attenuated the progression of pulmonary fibrosis in vivo and in vitro.

Kojin Murakami

Poster

Abstract

LSC - 2024 - Dissecting the role of microRNAs and cellular aging in the pathophysiology of Idiopathic Pulmonary Fibrosis

Giulia Zandomenego

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}